NASDAQ
SLN

Silence Therapeutics PLC

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Silence Therapeutics PLC Stock Price

Vitals

Today's Low:
$8.785
Today's High:
$9.49
Open Price:
$8.785
52W Low:
$4.545
52W High:
$17.99
Prev. Close:
$8.96
Volume:
17298

Company Statistics

Market Cap.:
$312.35 million
Book Value:
0.334
Revenue TTM:
$28.61 million
Operating Margin TTM:
-170.5%
Gross Profit TTM:
$6.62 million
Profit Margin:
-144.93%
Return on Assets TTM:
-34.63%
Return on Equity TTM:
-1103.54%

Company Profile

Silence Therapeutics PLC had its IPO on 2020-09-08 under the ticker symbol SLN.

The company operates in the Healthcare sector and Biotechnology industry. Silence Therapeutics PLC has a staff strength of 122 employees.

Stock update

Shares of Silence Therapeutics PLC opened at $8.79 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.79 - $9.49, and closed at $9.35.

This is a +4.35% increase from the previous day's closing price.

A total volume of 17,298 shares were traded at the close of the day’s session.

In the last one week, shares of Silence Therapeutics PLC have increased by +10%.

Silence Therapeutics PLC's Key Ratios

Silence Therapeutics PLC has a market cap of $312.35 million, indicating a price to book ratio of 12.7858 and a price to sales ratio of 31.6706.

In the last 12-months Silence Therapeutics PLC’s revenue was $28.61 million with a gross profit of $6.62 million and an EBITDA of $-48453000. The EBITDA ratio measures Silence Therapeutics PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Silence Therapeutics PLC’s operating margin was -170.5% while its return on assets stood at -34.63% with a return of equity of -1103.54%.

In Q2, Silence Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 149.9%.

Silence Therapeutics PLC’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Silence Therapeutics PLC’s profitability.

Silence Therapeutics PLC stock is trading at a EV to sales ratio of 14.8695 and a EV to EBITDA ratio of -5.5612. Its price to sales ratio in the trailing 12-months stood at 31.6706.

Silence Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$92.71 million
Total Liabilities
$19.56 million
Operating Cash Flow
$0
Capital Expenditure
$3000
Dividend Payout Ratio
0%

Silence Therapeutics PLC ended 2024 with $92.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $92.71 million while shareholder equity stood at $12.26 million.

Silence Therapeutics PLC ended 2024 with $0 in deferred long-term liabilities, $19.56 million in other current liabilities, 5512000.00 in common stock, $-282762000.00 in retained earnings and $7.77 million in goodwill. Its cash balance stood at $29.72 million and cash and short-term investments were $50.22 million. The company’s total short-term debt was $198,000 while long-term debt stood at $0.

Silence Therapeutics PLC’s total current assets stands at $82.31 million while long-term investments were $284000.00 and short-term investments were $20.50 million. Its net receivables were $25.32 million compared to accounts payable of $12.20 million and inventory worth $0.

In 2024, Silence Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $3000.

Comparatively, Silence Therapeutics PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$9.35
52-Week High
$17.99
52-Week Low
$4.545
Analyst Target Price
$39.48

Silence Therapeutics PLC stock is currently trading at $9.35 per share. It touched a 52-week high of $17.99 and a 52-week low of $17.99. Analysts tracking the stock have a 12-month average target price of $39.48.

Its 50-day moving average was $6.68 and 200-day moving average was $9.17 The short ratio stood at 3.32 indicating a short percent outstanding of 0%.

Around 3187.1% of the company’s stock are held by insiders while 5236.1% are held by institutions.

Frequently Asked Questions About Silence Therapeutics PLC

The stock symbol (also called stock or share ticker) of Silence Therapeutics PLC is SLN

The IPO of Silence Therapeutics PLC took place on 2020-09-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$8.65
0.02
+0.23%
$2721.9
-127.1
-4.46%
$724.55
-47.2
-6.12%
$38.92
1.42
+3.79%
$16.85
0
0%
$266.4
26.1
+10.86%
$1.08
-0.01
-0.92%
$3348.7
-111.35
-3.22%
$13.27
-0.51
-3.7%
$84.59
-2.51
-2.88%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence’s mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Address

72 Hammersmith Road, London, United Kingdom, W14 8TH